How AI Technology Could Help Manage Type 2 Diabetes

Translate to Spanish or other 102 languages!

A new study from Cleveland Clinic shows the benefits of using AI technology to help monitor and treat individuals with type2 diabetes. Image for illustration purposes
A new study from Cleveland Clinic shows the benefits of using AI technology to help monitor and treat individuals with type2 diabetes. Image for illustration purposes
- Advertisement -

CLEVELAND CLINIC – A new study from Cleveland Clinic shows the benefits of using AI technology to help monitor and treat individuals with type2 diabetes. 

Kevin Pantalone, MD, who is an endocrinologist at Cleveland Clinic, explains how it works. 

“The patients were randomized in the study to either the usual care group, which is where they received the usual recommended care for patients with type 2 diabetes through their primary care provider, or they were randomized to the Twin Precision treatment system, which is an artificially intelligence-enabled system that bundles sensors and health coaching to give patients individualized recommendations in real time to help them control their blood sugar,” said Dr. Pantalone. 

- Advertisement -

Dr. Pantalone led the research and said the AI technology is linked to an app on the participant’s cellphone and tracks in real time their blood sugar, body weight, blood pressure, and physical activity. 

Based on those numbers, it will then recommend different food choices or physical activity to help manage their diabetes. 

He said the study found that after 12 months, 71% of users were able to reach their A1C target level of less than 6.5% without glucose-lowering medications, except Metformin. 

Of the non-users, only 2.4% were able to achieve the same.

- Advertisement -

Those who used the technology also reported a reduction in their body weight and were able to wean off other therapies. 

“It was very surprising to see the extent of the de-intensification of therapy in patients that were in the clinical trial in the intervention group, specifically with some of thenewer therapies like GLP-1 receptor agonist, SGLT2 inhibitors. Across the board in the intervention group, we saw a significant decrease in the number of these therapies being utilized by the patients at 12 months, whereas in the usual care group, it either remained the same or in some instances, there was an increase in the utilization of therapies, which there specifically was an increase in the usual care group with the GLP-1 receptor agonist,” said Dr. Pantalone.

He added that no one demographic did better than another, which suggests most individuals could potentially use the technology.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Recognizes November as “National Hospice and Palliative Care” Month

DHR Health is pleased to recognize November as “National Hospice and Palliative Care Month.”  As we highlight National Hospice and Palliative Care Month, let us remember that healthcare is not solely about treating diseases but also about care for people at end of life.

STHS Heart Earns Healthgrades Five-Star Rating for Pacemaker Procedures

Healthgrades, the leading online resource for information about physicians and hospitals, has named STHS Heart a Five-Star Recipient for Pacemaker Procedures in 2027 for the second consecutive year, recognizing the facility's superior clinical outcomes and commitment to patient care.

AMA Advises Patients to Check with Doctors on Web Advice

The internet offers no shortage of health advice. But with misleading medical claims spread across social media, search engines, and AI platforms, finding trustworthy answers can be a challenge. 

FDA Authorizes Focused Ultrasound Treatment for Varicose Veins

Theraclion has announced that the US Food and Drug Administration (FDA) has granted De Novo authorization for its Sonovein device to treat superficial venous reflux in great saphenous veins (GSV), the main cause of varicose veins. This is the first noninvasive focused ultrasound platform to treat varicose veins, which affect approximately one third of adults.
- Advertisement -